➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
Johnson and Johnson
Merck
Boehringer Ingelheim
Harvard Business School

Last Updated: September 29, 2020

DrugPatentWatch Database Preview

Selinexor - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic sources for selinexor and what is the scope of freedom to operate?

Selinexor is the generic ingredient in one branded drug marketed by Karyopharm Theraps and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Selinexor has eighty-nine patent family members in thirty-three countries.

Summary for selinexor
International Patents:89
US Patents:5
Tradenames:1
Applicants:1
NDAs:1
Bulk Api Vendors: 25
Clinical Trials: 78
Patent Applications: 127
DailyMed Link:selinexor at DailyMed
Recent Clinical Trials for selinexor

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Peter MacCallum Cancer Centre, AustraliaPhase 3
OncotherapeuticsPhase 1
Karyopharm Therapeutics IncPhase 2/Phase 3

See all selinexor clinical trials

US Patents and Regulatory Information for selinexor

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Karyopharm Theraps XPOVIO selinexor TABLET;ORAL 212306-001 Jul 3, 2019 RX Yes Yes   Start Trial   Start Trial   Start Trial
Karyopharm Theraps XPOVIO selinexor TABLET;ORAL 212306-001 Jul 3, 2019 RX Yes Yes   Start Trial   Start Trial   Start Trial
Karyopharm Theraps XPOVIO selinexor TABLET;ORAL 212306-001 Jul 3, 2019 RX Yes Yes   Start Trial   Start Trial   Start Trial
Karyopharm Theraps XPOVIO selinexor TABLET;ORAL 212306-001 Jul 3, 2019 RX Yes Yes   Start Trial   Start Trial   Start Trial
Karyopharm Theraps XPOVIO selinexor TABLET;ORAL 212306-001 Jul 3, 2019 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Medtronic
Harvard Business School
McKinsey
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.